Pear’s apps guide users through behavioral therapy. Pear Therapeutics, which has three FDA-cleared prescription apps to help treat substance use disorder and insomnia, filed for bankruptcy on ...

Sandoz decision to step away from its trumpeted collaboration with Pear Tx on digital therapeutics doesn’t detract from the “huge opportunity” in the emerging, says analyst ...

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics, today provides an update on significant progress in its ...

Less than two years after Pear Therapeutics went public in a SPAC deal worth $1.6 billion, its assets were sold in an auction for just $6 million.

Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business. Prospective buyers can pick ...

Digital therapeutics pioneer Pear’s treatments get a second life, a year after bankruptcy. PursueCare, which bought some of Pear’s assets, is relaunching apps for treating substance use disorders.

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines ...

Pear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp. announced today that the U.S ...

But its revenue numbers still show a challenge in getting therapeutics to patients. By the end of 2021, Pear expects to bring in just $4 million in revenue, according to an investor presentation ...

Pear Therapeutics said Tuesday that it will become a publicly traded company through a merger with a special purpose acquisition company, or SPAC. The deal values the combined company at about $1. ...